|
| Figure 2: Individual peak plasma concentration (Cmax) (A), area under the concentration (AUC) (B),apparent oral clearance (CL/F) (C) and apparent volume of distribution (Vd/F) (D) of fexofenadine in 12 healthy volunteers after a single 120 mg oral dose of fexofenadine hydrochloride, following a 10-day treatment with resveratrol 500 mg once daily. |
